Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
Status:
Recruiting
Trial end date:
2028-02-28
Target enrollment:
Participant gender:
Summary
This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver
transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified
Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to
assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral
therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and
seronegative (R-) (D+R-) liver transplant recipients (LTxRs). A protocol-mandated preemptive
therapy (PET) will be used for CMV disease prevention in D+R- LTxRs.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)